Johnson & Johnson : Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer -December 21, 2023 at 08:44 am EST

News Release


Media Contacts:


Zayn Qureshi


+44 7760 334666 Email: zqureshi@its.jnj.com


Investor...

Related Keywords

Singapore ,Beerse ,Region Flamande ,Belgium ,Hoboken ,United States ,American ,Catherine Taylor ,Kiran Patel ,Zayn Qureshi ,Janssen Research Development ,Janssen Biotech Inc ,European Union ,Janssen Pharmaceutical Companies Of Johnson ,Johnson ,Clinical Development ,National Cancer Institute ,American Lung Association ,European Society Of Medical Oncology ,Janssen Research ,European Medicines Agency ,Cilag Gmbh International ,Agency Seeking Approval Of Lazertinib ,European Commission ,Exchange Commission ,European Society For Medical Oncology ,Companies Of Johnson ,Yuhan Corporation ,News Release ,Submits Marketing Authorisation Application ,European Medicines ,Seeking Approval ,First Line Treatment ,Late Breaking Presidential Symposium ,Janssen Pharmaceutical Companies ,Vice President ,Therapy Area Strategy ,Solid Tumors ,Medical Oncology ,Clinical Oncologyin ,Janssen Biotech ,Product Characteristics ,Pharmaceutical Companies ,Pulmonary Hypertension ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Response Evaluation Criteria ,Plus Lazertinib ,Patients With ,Advanced Non Small Cell Lung Cancer ,Primary Results From ,Results From ,Lazertinib Combination Therapy Versus Osimertinib ,Metastatic Non Small Cell Lung Cancer ,Accessed December ,Amivantamab Summary ,Diverse Models ,Met Bispecific Antibody ,Induces Receptor Downmodulation ,Antitumor Activity ,Mol Cancer ,Novel Bispecific Antibody Targeting ,Met Is Effective ,Resistant Lung ,Lung Cancer Res ,World Conference ,Lung Cancer Annual Meeting ,Accessed October ,Statistics Review ,National Cancer ,Year Survival ,Mutant Metastatic Lung Adenocarcinoma Treated ,Rev Dis ,Markets ,